ASR Vermogensbeheer N.V. Takes $117.03 Million Position in Eli Lilly and Company (NYSE:LLY)

Key Points

• ASR Vermogensbeheer N.V. has acquired 141,709 shares of Eli Lilly and Company, valued at approximately $117 million, making it the 8th largest holding in their portfolio.
• Institutional investors and hedge funds own 82.53% of Eli Lilly's stock, indicating significant institutional interest in the company.
• The stock has a consensus rating of "Moderate Buy" and an average target price of $1,012.56, despite mixed analyst ratings and recent price objective adjustments.

ASR Vermogensbeheer N.V. acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 141,709 shares of the company's stock, valued at approximately $117,030,000. Eli Lilly and Company makes up about 1.7% of ASR Vermogensbeheer N.V.'s holdings, making the stock its 8th biggest position.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Citizens Financial Group Inc. RI increased its position in shares of Eli Lilly and Company by 4.5% during the first quarter. Citizens Financial Group Inc. RI now owns 56,465 shares of the company's stock worth $46,635,000 after acquiring an additional 2,418 shares during the period. Wharton Business Group LLC grew its stake in shares of Eli Lilly and Company by 9.9% during the first quarter. Wharton Business Group LLC now owns 665 shares of the company's stock worth $549,000 after purchasing an additional 60 shares in the last quarter. Hemington Wealth Management increased its holdings in Eli Lilly and Company by 14.4% in the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock valued at $813,000 after buying an additional 124 shares during the last quarter. Fi3 FINANCIAL ADVISORS LLC raised its stake in Eli Lilly and Company by 0.7% in the first quarter. Fi3 FINANCIAL ADVISORS LLC now owns 15,019 shares of the company's stock valued at $12,405,000 after buying an additional 102 shares in the last quarter. Finally, Nicholas Hoffman & Company LLC. lifted its holdings in Eli Lilly and Company by 0.8% during the 1st quarter. Nicholas Hoffman & Company LLC. now owns 9,706 shares of the company's stock worth $8,016,000 after buying an additional 77 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

LLY stock traded down $106.20 during trading on Thursday, reaching $640.17. 26,056,463 shares of the company were exchanged, compared to its average volume of 3,684,957. The company has a market cap of $606.71 billion, a P/E ratio of 52.09, a PEG ratio of 1.06 and a beta of 0.44. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The stock's 50 day moving average price is $776.36 and its 200 day moving average price is $799.60. Eli Lilly and Company has a 52-week low of $633.20 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the business earned $3.92 earnings per share. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.9%. Eli Lilly and Company's payout ratio is presently 48.82%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Morgan Stanley reiterated an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Wall Street Zen upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $999.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.